Intestinal failure associated liver disease, Long-term parenteral support
TARAProtara TherapeuticsCatalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for IV Choline chloride in Intestinal failure associated liver disease, Long-term parenteral support. The expected timing is based on the latest available company guidance and may change.
THRIVE-3 trial. 11/10/25- Dose first patient by YE 2025. 01/07/26:- THRIVE-3 dosing underway; Phase 2b/3 interim analysis expected in H2 2026. 01/12/26:- First patient dosed in THRIVE-3 registrational trial. Interim Phase 2b/3 analysis remains expected in H2 2026. 03/10/26:- THRIVE-3 registrational trial ongoing; interim Phase 2b/3 results remain expected in 2H 2026. 05/13/26:- THRIVE-3 Phase 3 trial ongoing; interim Phase 2b/3 results still expected in H2 2026. 08/11/26:- THRIVE-3 Phase 3 interim results expected Q4 2026.
Verification
Confirm timing and program details against the company announcement or filing.